Article Menu
Need Help?
No Article Versions Notes Found
Cite
Chang, M.C.; Souter, L.H.; Kamel-Reid, S.; Rutherford, M.; Bedard, P.; Trudeau, M.; Hart, J.; Eisen, A.; , the Molecular Oncology Advisory Committee. Clinical Utility of Multigene Profiling Assays in Early-Stage Breast Cancer. Curr. Oncol. 2017, 24, 403-422. https://doi.org/10.3747/co.24.3595
Chang MC, Souter LH, Kamel-Reid S, Rutherford M, Bedard P, Trudeau M, Hart J, Eisen A, the Molecular Oncology Advisory Committee. Clinical Utility of Multigene Profiling Assays in Early-Stage Breast Cancer. Current Oncology. 2017; 24(5):403-422. https://doi.org/10.3747/co.24.3595
Chicago/Turabian StyleChang, M. C., L. H. Souter, S. Kamel-Reid, M. Rutherford, P. Bedard, M. Trudeau, J. Hart, A. Eisen, and the Molecular Oncology Advisory Committee. 2017. "Clinical Utility of Multigene Profiling Assays in Early-Stage Breast Cancer" Current Oncology 24, no. 5: 403-422. https://doi.org/10.3747/co.24.3595
APA StyleChang, M. C., Souter, L. H., Kamel-Reid, S., Rutherford, M., Bedard, P., Trudeau, M., Hart, J., Eisen, A., & , the Molecular Oncology Advisory Committee. (2017). Clinical Utility of Multigene Profiling Assays in Early-Stage Breast Cancer. Current Oncology, 24(5), 403-422. https://doi.org/10.3747/co.24.3595
